Drug Trial Radar · NCT00418886
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
698
Actual
Start
Jan 2007
Primary completion
Sep 2008
Study completion Feb 14, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone.
Conditions
- Non Small Cell Lung Cancer
- Lung Cancer
Interventions
VandetanibDrug
oral once daily tablet
PemetrexedDrug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) in the Overall PopulationTime frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
- Progression-Free Survival in the Female PopulationTime frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Locations
110 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Casa Grande, Arizona
Research Site
Chandler, Arizona
Research Site
Farmington, Connecticut
Research Site
Stamford, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Orlando, Florida
Research Site
Gainesville, Georgia
Research Site
Skokie, Illinois
Research Site
Sioux City, Iowa
Research Site
Mount Sterling, Kentucky
Research Site
Portland, Maine
Research Site
Baltimore, Maryland
Research Site
Rockville, Maryland
Research Site
Boston, Massachusetts
Research Site
St Louis, Missouri
Research Site
Mineola, New York
Research Site
Rochester, New York
Research Site
Winston-Salem, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Middletown, Ohio
Research Site
Hilton Head Island, South Carolina
Research Site
Austin, Texas
Research Site
Salt Lake City, Utah
Research Site
Avellaneda, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
La Plata, Argentina
Research Site
Ramos Mejía, Argentina
Research Site
Salta, Argentina
Research Site
Santa Fe, Argentina
Research Site
Chermside, Australia
Research Site
Fitzroy, Australia
Research Site
Footscray, Australia
Research Site
Heidelberg, Australia
Research Site
Randwick, Australia
Research Site
St Leonards, Australia
Research Site
Wodonga, Australia
Research Site
Brussels (Woluwé-St-Lambert), Belgium
Research Site
Leuven, Belgium
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.